



(11) **EP 1 370 277 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
06.04.2011 Bulletin 2011/14

(21) Application number: **02701842.3**

(22) Date of filing: **28.02.2002**

(51) Int Cl.:
A61K 38/11 (2006.01) A61P 5/10 (2006.01)

(86) International application number:
PCT/SE2002/000362

(87) International publication number:
WO 2002/067974 (06.09.2002 Gazette 2002/36)

(54) **USE OF OXYTOCIN FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION AGAINST CANCER IN SITU AND CERVICITIS**

VERWENDUNG VON OXYTOCIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG GEGEN KARZINOM IN SITU UND ZERVIZITIS

UTILISATION DE L'OCYTOCINE DANS LA PREPARATION D'UNE COMPOSITION PHARMACEUTIQUE CONTRE LE CANCER IN SITU ET LA CERVICITE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: **28.02.2001 SE 0100684**

(43) Date of publication of application:
17.12.2003 Bulletin 2003/51

(73) Proprietors:
• **Uvnäs-Moberg, Kerstin**
182 62 Djursholm (SE)
• **Lundeberg, Thomas**
181 31 Lidingö (SE)

(72) Inventors:
• **Uvnäs-Moberg, Kerstin**
182 62 Djursholm (SE)
• **Lundeberg, Thomas**
181 31 Lidingö (SE)

(74) Representative: **Skoglösa, Ylva**
Valea AB
Box 7086
103 87 Stockholm (SE)

(56) References cited:
WO-A1-00/18424 WO-A1-01/78758
DE-A1- 4 236 293 US-A- 4 402 942

- **GIANNI BUSSOLATI ET AL.:** 'In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-lys 8-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors' **CANCER RESEARCH** vol. 61, 2001, pages 4393 - 4397, XP002951746
- **PAOLA CASSONI ET AL.:** 'Oxytocin receptor in human adenocarcinomas of the endometrium: presence and biological significance' **JOURNAL OF PATHOLOGY** vol. 190, 2000, pages 470 - 477, XP002951747
- **DATABASE CA [Online] SIMEK, PETR ET AL.:** 'Preparation of [2-(O-methyltyrosine)] deamino-1-carbaoxytocin by a combined solid phase and solution method', XP002951748 Retrieved from STN Database accession no. 111:233675 & CS 255 616 B1 15 March 1988
- **DATABASE CAPLUS [Online] DOC. NO. 70:47836 AOYAGI, HARUHIKO ET AL.:** 'Analogues of oxytocin containing leucinamide and glycylglycinamide in place of glycinamide', XP002951749 Retrieved from STN Database accession no. 1969:47836 & BULL. CHEM. SOC. JAP. vol. 41, no. 11, 1968, pages 2772 - 2776
- **DATABASE CA [Online] FREIDINGER, ROGER ET AL.:** 'Titanium (III) as a selective reducing agent for nitroarginyl peptides: synthesis of arginine vasotocin', XP002951750 Retrieved from STN Database accession no. 90:6683 & J. ORG. CHEM. vol. 43, no. 25, 1978, pages 4800 - 4803

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


EP 1 370 277 B1

Description

[0001] The present invention relates to the use of substances with oxytocin activity for the preparation of a pharmaceutical composition against a pre-cancerous disease state in the cervix and cervicitis. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against a pre-cancerous disease state in the cervix and cervicitis. It also relates to a compound of the formula SEQ ID NO: 2.

Background of the invention

[0002] Oxytocin was one of the first peptide hormones to be isolated and sequenced. It is a nonapeptide with two cysteine residues that form a disulfide bridge between positions 1 and 6 and corresponds to the formula



[0003] For a long time the only effects attributed to oxytocin were its stimulating effects on milk ejection and uterine contractions, but in the past decades it has been shown that oxytocin exerts a wide spectrum of effects within the central nervous system, CNS. It has been suggested that oxytocin participates in the control of memory and learning processes and of various types of behaviour such as feeding, locomotion, as well as maternal and sexual behaviour. Oxytocin is also suggested to participate in the control of cardiovascular functions, thermoregulation, and pain threshold and fluid balance. There is also evidence that oxytocin is involved in the control of various immunological processes. It has recently been demonstrated that oxytocin injections cause a lowering of blood pressure and increased weight gain - long lasting effects after repetitive administration. As a central stimulating substance oxytocin plays an important role in the interaction between mother and progeny in mammals. The products may also be used prophylactic in young human beings e.g. already in new born babies or young children to prevent the development of diseases later on in life which diseases are dependent on stress conditions during the fetal life. Such conditions may be heart/vessel diseases such as stroke, heart infarct, hypertension, and diabetes.

[0004] In the human body oxytocin is produced in the paraventricular nucleus, PVN, and the supraoptic nucleus, SON, of the hypothalamus. It differs by only two amino acids from vasopressin, which is also produced in these nuclei. The magnocellular oxytocinergic neurones of the SON and PVN send axons to the posterior pituitary from which oxytocin is released into the circulation. Parvocellular neurones that originate in the PVN project into multiple areas within CNS. The oxytocin-producing cells are innervated by cholinergic, catecholaminergic as well as peptidergic neurones. The presence of oxytocin in different tissues outside the brain, such as the uterus, ovaries, testis, thymus, adrenal medulla and pancreas has been demonstrated and oxytocin is suggested to exert local effects in these organs.

[0005] A parallel secretion of oxytocin into the brain regions and into the circulation occurs in response to some stimuli such as suckling, but other stimuli can cause separate activation of oxytocinergic neurones, terminating in the brain or the pituitary.

[0006] It has now turned out that oxytocin has a relieving effect on cancer in situ and cervicitis.

[0007] There are several oxytocin derivatives, i.e. compounds with a structure similar to that of oxytocin. There are preliminary indications that other oxytocin derivatives than oxytocin could give the effects against cancer in situ and cervicitis as well as parts of the oxytocin molecule. No publications describe the use of oxytocin or any other oxytocin derivatives or parts of the oxytocin molecule to have effects against cancer in situ and cervicitis.

[0008] By the expression "cancer in situ and cervicitis" we understand consequences of diseases in vagina and cervix originating from infections, as well as inflammations. In the context of the invention, cancer in situ is related to the cervix. Such diseases include, besides cancer in situ and cervicitis, also precancerous disease states, squamous cell carcinoma, and koilocytosis. By cancer in situ is meant a neoplastic entity wherein the tumour cells are confined to the epithelium of origin, without invasion of the basement membrane. By cervicitis is meant inflammation of the cervix uteri i.e. the lower and narrow end of the uterus, between the isthmus and the ostium uteri. The epithelium of the cervix uteri is quite different from the epithelium of the rest of the uterus. Koilocytosis is a consequence of herpes virus.

[0009] Bussolati et al., Cancer Research, Volume 61, June 2001, p. 4393-4397, describes that oxytocin derivatives may have effects against OTR-positive tumours, such as breast and endometrial carcinomas, neuroblastomas, and glioblastomas. Furthermore, Cassoni et al., Journal of Pathology, Volume 190, 2000, p. 470-477, describes that oxytocin reduces cell proliferation in breast cancer cells, in neural neoplastic cells, as well as in a human endometrial carcinoma

cell line. However, these documents relate to the treatment of advanced cancer forms, whereas the present invention relates to the treatment of cancer at a very early stage, e.g. precancerous disease states as mentioned above. The effects of oxytocin derivatives against such an early cancer are most probably due to antioxidant effects of oxytocin or metabolites thereof such as cysteine and N-acetylcysteine. In van Zandwijk et al., J Cell Biochem Suppl 1995, Vol. 22, p. 24-32, it is stated that the antimutagenic and anticarcinogenic effects of N-acetylcysteine could be ascribed to e.g. the antioxidant activity thereof.

[0010] It has now turned out that oxytocin improves recovery of cancer in situ and cervicitis (Example 1). This example indicates that oxytocin or that substances with oxytocin activity may be used against cancer in situ and cervicitis. However, it should be noted that it is not necessary that the patients treated according to Example 1 have postmenopausal disorders before treatment.

[0011] The effect of oxytocin can be extended or strengthened by administration in combination with drugs increasing the release of oxytocin and/or the number or the affinity of oxytocin receptors. One such drug is oestrogen. The effect of oxytocin can also be extended or strengthened by administration in combination with drugs having an α_2 -agonistic effect. One such drug is clonidine.


Summary of the invention

[0012] The present invention relates to the use of at least one substance with oxytocin activity for the preparation of a pharmaceutical composition against a pre-cancerous disease state in the cervix and cervicitis. The invention also relates to a pharmaceutical composition comprising an effective concentration of at least one substance with oxytocin activity in mixture or otherwise together with at least one pharmaceutically acceptable carrier or excipient. Such a pharmaceutical composition could be used in order to achieve a relieving effect on a pre-cancerous disease state in the cervix and cervicitis.

Detailed description of the invention

[0013] One object of the present invention is the use of at least one substance with oxytocin activity for the preparation of a pharmaceutical composition against a pre-cancerous disease state in the cervix and cervicitis

[0014] It is preferred that the at least one substance is selected from the group consisting of the following compounds:



wherein

X₁ is selected from the group consisting of Cys, Mpa and nothing,

X₂ is selected from the group consisting of Tyr, (O-methyl-Tyr), Phe, and nothing,

X₃ is selected from the group consisting of Ile, Val, Hoph, Phe, Cha, and nothing,

X₄ is selected from the group consisting of Gln, Ser, Thr, Cit, Arg, and Daba,

X₅ is selected from the group consisting of Pro, and nothing,

X₆ is selected from the group consisting of Ile, Leu, nothing, Val, Hos, Daba, Thr, Arg, and Cit,

X₇ is selected from the group consisting of Gly, nothing, and Ala,

X₈ is selected from the group consisting of Gly, and nothing,


X₉ is selected from the group consisting of CH₂ and S;

as well as salts thereof.


[0015] The cystein disulfide bridge is only present when X₁ represents Cys or Mpa, X₂ represents Tyr, (O-methyl-Tyr) or Phe, and X₃ represents Ile, Val, Hoph, Phe or Cha.

[0016] By "nothing" is meant that the letters respectively may have no meaning or may represent a bond and that there may be a direct bond between the items (letter, atom or group) situated to the right and to the left, respectively, of the letter designating "nothing". For example, in SEQ ID NO: 2 above, when only X₁ designates nothing, the resulting molecule corresponds to X₂-X₃-X₄-Asn-Cys-X₅-X₆-X₇-X₈-NH₂. When only X₈ designates nothing, the X₇ residue is amidated.


[0017] It is even more preferred that the at least one substance is selected from the group consisting of the following compounds:




X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Leu; X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7




X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Ile, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7




X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Ser, X₅ is Pro, X₆ is Ile, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7



X₁ is Cys, X₂ is Phe, X₃ is Val, X₄ is Arg, X₅ is Pro, X₆ is Thr, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7




X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Arg, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7




X₁ is Cys, X₂ is Tyr, X₃ is Phe, X₄ is Gln, X₅ is Pro, X₆ is Arg, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7




10
 X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is Gly,
 and X₉ is S in Claim 2 and 7



20
 X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅-X₈ is nothing, and X₉ is S in Claim 2, 7,
 and 11



30
 X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆-X₈ is nothing, and X₉ is S in Claim 2 and 7



40
 X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇-X₈ is nothing, and X₉ is S in Claim 2 and 7
 Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂

40
SEQ ID NO: 12

X₁ is nothing, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2, 7, and 11
 Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂

45
SEQ ID NO: 13

X₁-X₂ is nothing, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is nothing,
 and X₉ is S in Claim 2, 7, and 11


Gln-Asn-Cys-Pro-Leu-Gly-NH₂

45
SEQ ID NO: 14

X₁-X₃ is nothing, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2, 7, and 11
 Ile-Gln-Asn-Cys-Pro-NH₂

50
SEQ ID NO: 15

X₁-X₂ is nothing, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆-X₈ is nothing, and X₉ is S in Claim 2, 7, and 11



X₁ is Cys, X₂ is Tyr, X₃ is Cha, X₄ is Cit, X₅ is Pro, X₆ is Arg, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7

5




SEQ ID NO: 17

10

X₁ is Cys, X₂ is Tyr, X₃ is Val, X₄ is Thr, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7

15



SEQ ID NO: 18

20

X₁ is Cys, X₂ is Tyr, X₃ is Hoph, X₄ is Thr, X₅ is Pro, X₆ is Val, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7

25



SEQ ID NO: 19

30

X₁ is Cys, X₂ is Tyr, X₃ is Phe, X₄ is Cit, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is nothing, and X₉ is S in Claim 2 and 7

35



SEQ ID NO: 20

X₁ is Cys, X₂ is Tyr, X₃ is Cha, X₄ is Arg, X₅ is Pro, X₆ is Hos, X₇ is Ala, X₈ is nothing, and X₉ is S in Claim 2 and 7

40




SEQ ID NO: 21

45

X₁ is Cys, X₂ is Tyr, X₃ is Val, X₄ is Daba, X₅ is Pro, X₆ is Daba, X₇ is Ala, X₈ is nothing, and X₉ is S in Claim 2 and 7


50




Cys-Tyr-Hoph-Daba-Asn-Cys-Pro-Cit-Ala-NH₂

55 SEQ ID NO: 22

X₁ is Cys, X₂ is Tyr, X₃ is Hoph, X₄ is Daba, X₅ is Pro, X₆ is Cit, X₇ is Ala, X₈ is nothing, and X₉ is S in Claim 2 and 7




10 X₁ is Cys, X₂ is Tyr, X₃ is Phe, X₄ is Arg, X₅ is Pro, X₆ is Val, X₇ is Ala, X₈ is nothing, and X₉ is S in Claim 2 and 7




20 X₁ is Mpa, X₂ is (O-methyl-Tyr), X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is nothing, and X₉ is CH₂ in Claim 2 and 7,


25 wherein Mpa stands for β -mercaptopropionic acid; wherein the CH₂-S-group thereof is bonded to the cystein portion via a thioether bond i position 6 giving the structure for SEQ ID NO: 24 as follows:




35 wherein (O-methyl-Tyr) stands for O-methyltyrosine of the chemical formula:




45 wherein Cha stands for cyclohexylalanine,




55 Hoph stands for homophenylalanine,




Cit stands for citrulline,



Daba stands for diaminobutyric acid, and



Hos stands for homoserine.



There are different processes described for the synthetical production of oxytocin; commercial processes are for instance described in US patents 2,938,891 and 3,076,797.

[0018] A substance with oxytocin activity refers, whenever applicable, in addition to oxytocin also to precursors, metabolic derivatives, oxytocin agonists or analogues displaying the same properties.

[0019] Annetocin has been isolated from the earthworm, as described in Oumi T, Ukena K, Matsushima O, Ikeda T, Fujita T, Minakata H, Nomoto K, Annetocin: an oxytocin-related peptide isolated from the earthworm, *Eisenia foetida*, *Biochem Biophys Res Commun* 1994, Jan 14; 198(1): 393-399. The uterotonic activity and myometrial receptor affinity of carbetocin is described in Atke A and Vilhardt H, *Acta Endocrinologica (Copenh)* 1987, 115: 155-160.

[0020] Other substances with oxytocin activity could also be used, such as naturally occurring or artificially modified variants, analogues, and derivatives of oxytocin, mesotocin, isotocin, and annetocin. Such substances could be obtained by addition, insertion, elimination, or substitution of at least one amino acid in these hormones. By a substance with an oxytocin like activity is also understood precursors, metabolites such as metabolic derivatives e.g. metabolic degradation products, agonists, or analogues of the substances mentioned herein displaying the same properties. When one or more amino acids are added to a substance with oxytocin activity, it is preferred to add 1-3 amino acids to the carboxyl terminal. Metabolic derivatives or metabolic degradation products may be oxytocin like peptides e.g. with nine amino acids such as oxytocin, mesotocin, isotocin, and annetocin from which one or more amino acids has been deleted from either the carboxyl terminal end or the amino terminal end or both the carboxyl terminal and the amino terminal end, preferably 1-3 amino acids from each terminal. It could be ascertained that these variants are analogues of oxytocin, mesotocin, isotocin or annetocin by immunological methods, e.g. RIA (radioimmunoassay), IRMA (radiometric methods), RIST (radioimmunosorbent test), and RAST (radioallergosorbent test). The invention also includes substances having at least 50, 60, 70, 80 and most preferably 90% homology to oxytocin, and showing oxytocin activity.

[0021] As mentioned above, there are indications that addition of one or more amino acids to the oxytocin molecule may give a molecule that has effects against inflammation.

One example of such a molecule is SEQ ID NO: 8.

[0022] As mentioned above, there are indications that subfragments of the oxytocin molecule have effects against inflammation. Examples of subfragments of the oxytocin molecule are the following compounds: SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15.

[0023] There is also a possibility to create new compounds with oxytocin activity by means of computer simulation. Methods for computer simulation are known by a person skilled in the art, e.g. as described in EP 0660 210 A2. Eight new compounds have been created by means of computer simulation, namely the following peptides: SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23.

5 [0024] The invention also relates to the peptides mentioned above in both D- and L-form. Especially the invention relates to the L-form. By inversion of the peptide sequence thereof, the D-form could be converted to the L-form. The effect of the D- and L-forms are the same. These and the peptides above can be produced by methods known to a person skilled in the art, e.g. according to Merrifield, P.B., "Solid Phase Synthesis", Angew. Chemie, 1985, No. 97, p. 801.

10 [0025] It is preferred that a substance with oxytocin activity is administered in an amount of 0.01-100 ng/kg body weight of the patient, in particular 0.1-10 ng/kg.

[0026] Another object of the invention is a pharmaceutical composition against a pre-cancerous disease state in the cervix and cervicitis comprising an effective concentration of at least one substance with oxytocin activity in mixture or otherwise together with at least one substance is selected from the group consisting of compounds with the formula SEQ ID NO: 2. It is even more preferred that the at least one substance is selected from the group consisting of the following compounds: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.

20 [0027] The pharmaceutical compositions according to the invention may contain substances that extend or strengthen the effects of oxytocin. Such substances could increase the release of oxytocin and/or the number or affinity of oxytocin receptors, such as oestrogen, or drugs having an α_2 -agonistic effect, such as clonidine.

[0028] It should be noted that salts of the compounds according to the invention are included within the scope of the invention. As examples of salts of the compounds are intended in particular pharmaceutically acceptable acid and base addition salts.

25 [0029] The expression "pharmaceutically acceptable acid addition salts" are intended to be any non-toxic organic or inorganic acid addition salt of the compounds of SEQ ID NO: 2. Examples of illustrative inorganic acids that form suitable salts are hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogensulphate. Examples of illustrative organic acids that form suitable salts are mono-, di- and tricarboxylic acids. Examples of such acids are acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, 2-phenoxybenzoic acid, and sulphonic acids such as p-toluenesulphonic acid, methanesulphonic acid and 2-hydroxyethanesulphonic acid. Such salts could either be in hydrated or anhydrous form. The acid addition salts of these compounds are generally water soluble and different hydrophilic organic solvents and, that compared to the free base forms thereof, generally display higher melting points.

30 [0030] The expression "pharmaceutically acceptable base addition salts" are intended to be any non-toxic organic or inorganic base addition salt of the compounds of SEQ ID NO: 2. Examples of illustrative inorganic bases that form suitable salts are alkali and earth alkali metal hydroxides and carbonates such as sodium hydroxide, sodium carbonate, potassium hydroxide, potassium carbonate, calcium hydroxide, calcium carbonate, magnesium hydroxide, magnesium carbonate and ammonia. Examples of illustrative organic bases that form suitable salts are methylamine, dimethylamine, trimethylamine and picoline. Either mono- or dibasic salts could be formed with such compounds. The base addition salts of these compounds are generally water soluble and different hydrophilic organic solvents and, that compared to the free base forms thereof, generally display higher melting points.

35 [0031] The pharmaceutical compositions are prepared in a manner known to a person skilled in the pharmaceutical art. The carrier or the excipient could be a solid, semisolid or liquid material that could serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are known in the art. The pharmaceutical composition could be adapted to oral, parenteral, intravaginal, or topical use and could be administered to the patient as tablets, capsules, suppositories, solutions, suspensions or the like.

40 [0032] The pharmaceutical compositions could be administered orally, e.g. with an inert diluent or with an edible carrier. They could be enclosed in gelatine capsules or be compressed to tablets. For oral therapeutic administration the compounds according to the invention could be incorporated with excipients and used as tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 4% by weight of the compounds according to the invention, the active ingredient, but could be varied according to the special form and could, suitably, be 4-70% by weight of the unit. The amount of the active ingredient that is contained in compositions is so high that a unit dosage form suitable for administration is obtained.

45 [0033] The tablets, pills, capsules, lozenges and the like could also contain at least one of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatine, excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, com starch, and the like, lubricants such as magnesium stearate or Sterotex,

glidants such as colloidal silica dioxide, and sweetening agents such as saccharose or saccharin could be added or flavourings such as peppermint, methyl salicylate or orange flavouring. When the unit dosage form is a capsule it could contain in addition to the type above a liquid carrier such as polyethylene glycol or a fatty oil. Other unit dosage forms could contain other different materials that modify the physical form of the unit dosage form, e.g. as coatings. Accordingly, tablets or pills could be coated with sugar, shellac or other enteric coating agents. A syrup could in addition to the active ingredient contain saccharose as a sweetening agent and some preservatives, dyes and flavouring agents. Materials that are used for preparation of these different compositions should be pharmaceutically pure and non-toxic in the amounts used.


[0034] For parenteral administration the compounds according to the invention could be incorporated in a solution or suspension. Parenteral administration refers to the administration not through the alimentary canal but rather by injection through some other route, as subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intravenous, intranasal, intrapulmonary, through the urinary tract, through eye drops, rectal or intravaginal (e.g. as a suppository, a vagitorium, a cream or an ointment), through the lactiferous tract in cattle, into an organ such as bone marrow, etc. Bone marrow may also be treated *in vitro*. These preparations could contain at least 0.1 % by weight of an active compound according to the invention but could be varied to be approximately 0.1-50% thereof by weight. The amount of the active ingredient that is contained in such compositions is so high that a suitable dosage is obtained.

[0035] The solutions or suspensions could also comprise at least one of the following adjuvants: sterile diluents such as water for injection, saline, fixed oils, polyethylene glycols, glycerol, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol or methyl paraben, antioxidants such as ascorbic acid or sodium bisulfite, chelating agents such as ethylene diamine tetraacetic acid, buffers such as acetates, citrates or phosphates, and agents for adjustment of the tonicity such as sodium chloride or dextrose. The parenteral preparation could be enclosed in ampoules, disposable syringes or multiple dosage vessels made of glass or plastic.

[0036] For topical administration the compounds according to the invention could be incorporated in a solution, suspension, or ointment. These preparations could contain at least 0.1 % by weight of an active compound according to the invention but could be varied to be approximately 0.1-50% thereof by weight. The amount of the active ingredient that is contained in such compositions is so high that a suitable dosage is obtained. The administration could be facilitated by applying touch, pressure, massage, heat, warmth, or infrared light on the skin, which leads to enhanced skin permeability. Hirvonen, J., Kalia, YN, and Guy, RH. Transdermal delivery of peptides by iontophoresis, *Nat Biotechnol* 1996 Dec; 14(13): 1710-1713 describes how to enhance the transport of a drug via the skin using the driving force of an applied electric field. Preferably, iontophoresis is effected at a slightly basic pH.

[0037] Other administration forms are inhalation through the lungs, buccal administration via the mouth, enteral administration via the small intestine, and local administration with a release, preferably a slow release, of the active substance e.g. in the form of a ring. All these administration forms could be effected by means known by a person skilled in the art.

[0038] Another object of the present invention is a compound of the formula (I):



wherein
either:

X₁ is Cys, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅-X₈ is nothing, and X₉ is S; or
X₁ is nothing, X₂ is Tyr, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is nothing, and X₉ is S; or
X₁-X₂ is nothing, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇ is Gly, X₈ is nothing, and X₉ is S; or
X₁-X₃ is nothing, X₄ is Gln, X₅ is Pro, X₆ is Leu, X₇ is Leu, X₈ is nothing, and X₉ is S; or
X₁-X₂ is nothing, X₃ is Ile, X₄ is Gln, X₅ is Pro, X₆-X₈ is nothing, and X₉ is S; as well as salts thereof.

[0039] By the expression "comprising" we understand including but not limited to. Thus, other non-mentioned substances, additives or carriers may be present.

[0040] The invention will be illuminated by the following Example, which is only intended to illuminate and not restrict the invention in any way.

EP 1 370 277 B1

Example 1- effect of oxytocin on cancer in situ and cervicitis in humans

[0041] *Patients.* 20 women, all aged 60-70 years, with postmenopausal disorders, participated in a double blind cross-over randomised protocol, which means that the patients receive both oxytocin and control treatment without knowing the order of the treatments.

[0042] *Experimental procedure.* The patients were treated with oxytocin 1 mg/ml mixed with 1 ml cellulose gel intravaginally during five consecutive days to relieve the postmenopausal disorders. However, it was discovered that one of the patients suffered from cancer in situ and cervicitis before the oxytocin treatment. This was established by the fact that the patient underwent a Pap smear test before the oxytocin treatment. In this test, cells desquamated from the genital epithelium are obtained by smears, fixed and stained, and examined under the microscope for evidence of pathologic changes. After the oxytocin treatment, the patient also underwent a Pap smear test.

[0043] *Results.* When comparing the results of the Pap smear tests before and after oxytocin administration, it was shown that the cancer in situ and cervicitis was removed, implying that oxytocin was efficient for the treatment of cancer in situ and cervicitis.

SEQUENCE LISTING

[0044]

<110> UVNÄS-MOBERG, KERSTIN

LUNDEBERG, THOMAS

<120> New subject-matter

<130> Cervix

<150> SE 0100684-0

<151> 2001-02-28

<160> 24

<170> PatentIn version 3.1

<210> 1

<211> 9

<212> PRT

<213> PEPTIDE

<220>

<221> MOD_RES

<222> (9)..(9)

<223> AMIDATION

<220>

<221> DISULFID

<222> (1)..(6)

<223>

<400> 1

Cys Tyr Ile Gln Asn Cys Pro Leu Gly

1

5

<210> 2

<211> 10

<212> PRT

<213> PEPTIDE

<220>

<221> MOD_RES

<222> (10)..(10)

<223> AMIDATION

<220>

<221> DISULFID

<222> (1)..(6)

<223> For X1 being Cys

<220>
 <221> THIOETH
 <222> (1)..(6)
 <223> For X1 being Mpa
 5 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Cys, Mpa or nothing
 <220>
 10 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Tyr, (O-methyl-Tyr), Phe or nothing
 <220>
 <221> MISC_FEATURE
 15 <222> (3)..(3)
 <223> Ile, Val, Hoph, Phe, Cha or nothing
 <220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 20 <223> Gln, Ser, Thr, Cit, Arg or Daba
 <220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Pro or nothing
 25 <220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> Ile, Leu, nothing, Val, Hos, Daba, Thr, Arg or Cit
 <220>
 30 <221> MISC_FEATURE
 <222> (9)..(9)
 <223> Gly, nothing or Ala
 <220>
 <221> MISC_FEATURE
 35 <222> (10)..(10)
 <223> Gly or nothing
 <400> 2

 40 **Xaa Xaa Xaa Xaa Asn Cys Xaa Xaa Xaa Xaa**
1 5 10

 <210> 3
 45 <211> 9
 <212> PRT
 <213> PEPTIDE
 <220>
 <221> MOD_RES
 50 <222> (9)..(9)
 <223> AMIDATION
 <220>
 <221> DISULFID
 <222> (1)..(6)
 55 <223>
 <400> 3

Cys Tyr Ile Gln Asn Cys Pro Ile Gly
1 5

5

<210> 4
<211> 9
<212> PRT
10 <213> PEPTIDE
<220>
<221 > MOD_RES
<222> (9)..(9)
<223> AMIDATION
15 <220>
<221> DISULFID
<222> (1)..(6)
<223>
<400> 4

20

Cys Tyr Ile Ser Asn Cys Pro Ile Gly

25

1 5

30

<210> 5
<211> 9
<212> PRT
<213> PEPTIDE
<220>
35 <221> MOD_RES
<222> (9)..(9)
<223> AMIDATION
<220>
<221> DISULFID
40 <222> (1)..(6)
<223>
<400> 5

40

45

Cys Phe Val Arg Asn Cys Pro Thr Gly
1 5

50

<210> 6
<211> 9
<212> PRT
<213> PEPTIDE
<220>
55 <221> MOD_RES
<222> (9)..(9)
<223> AMIDATION
<220>
<221> DISULFID

55

<222> (1)..(6)
<223>
<400> 6

5

Cys Tyr Ile Gln Asn Cys Pro Arg Gly
1 5

10 <210> 7
<211> 9
<212> PRT
<213> PEPTIDE
<220>
15 <221> MOD_RES
<222> (9)..(9)
<223> AMIDATION
<220>
<221> DISULFID
20 <222> (1)..(6)
<223>
<400> 7

25

Cys Tyr Phe Gln Asn Cys Pro Arg Gly
1 5

30 <210> 8
<211> 10
<212> PRT
<213> PEPTIDE
<220>
<221> MOD_RES
35 <222> (10)..(10)
<223> AMIDATION
<220>
<221> DISULFID
<222> (1)..(6)
40 <223>
<400> 8

45

Cys Tyr Ile Gln Asn Cys Pro Leu Gly Gly
1 5 10

<210> 9
<211> 6
50 <212> PRT
<213> PEPTIDE
<220>
<221> MOD_RES
<222> (6)..(6)
55 <223> AMIDATION
<220>
<221> DISULFID
<222> (1)..(6)

<223>
<400> 9

5 **Cys Tyr Ile Gln Asn Cys**
 1 5

<210> 10
10 <211> 7
 <212> PRT
 <213> PEPTIDE
 <220>
 <221> MOD_RES
15 <222> (7)..(7)
 <223> AMIDATION
 <220>
 <221> DISULFID
 <222> (1)..(6)
20 <223>
 <400> 10

25 **Cys Tyr Ile Gln Asn Cys Pro**
 1 5

<210> 11
30 <211> 8
 <212> PRT
 <213> PEPTIDE
 <220>
 <221> MOD_RES
35 <222> (8)..(8)
 <223> AMIDATION
 <220>
 <221> DISULFID
 <222> (1)..(6)
40 <223>
 <400> 11

45 **Cys Tyr Ile Gln Asn Cys Pro Leu**
 1 5

<210> 12
50 <211> 8
 <212> PRT
 <213> PEPTIDE
 <220>
 <221> MOD_RES
 <222> (8)..(8)
55 <223> AMIDATION
 <400> 12

Tyr Ile Gln Asn Cys Pro Leu Gly
1 5

5
 <210> 13
 <211> 7
 <212> PRT
 <213> PEPTIDE
 10
 <220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> AMIDATION
 <400> 13

Ile Gln Asn Cys Pro Leu Gly
1 5

20
 <210> 14
 <211> 6
 <212> PRT
 <213> PEPTIDE
 25
 <220>
 <221> MOD_RES
 <222> (6)..(6)
 <223> AMIDATION
 <400> 14

Gln Asn Cys Pro Leu Gly
1 5

30
 <210> 15
 <211> 5
 <212> PRT
 <213> PEPTIDE
 40
 <220>
 <221> MOD_RES
 <222> (5)..(5)
 <223> AMIDATION
 <400> 15

Ile Gln Asn Cys Pro
1 5

50
 <210> 16
 <211> 9
 <212> PRT
 <213> PEPTIDE
 55
 <220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> AMIDATION

Cys Tyr Xaa Thr Asn Cys Pro Val Gly
 1 5

5

<210> 19
 <211> 9
 <212> PRT
 <213> PEPTIDE
 <220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> AMIDATION
 <220>
 <221> DISULFID
 <222> (1)..(6)
 <223>
 <220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Cit
 <400> 19

10

15

20

25

Cys Tyr Phe Xaa Asn Cys Pro Leu Gly
 1 5

30

<210> 20
 <211> 9
 <212> PRT
 <213> PEPTIDE
 <220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> AMIDATION
 <220>
 <221> DISULFID
 <222> (1)..(6)
 <223>
 <220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> Cha
 <220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> Hos
 <400> 20

35

40

45

50

Cys Tyr Xaa Arg Asn Cys Pro Xaa Ala
 1 5

55

<210> 21
 <211> 9

<212> PRT
 <213> PEPTIDE
 <220>
 <221>MOD_RES
 5 <222> (9)..(9)
 <223> AMIDATION
 <220>
 <221> DISULFID
 <222> (1)..(6)
 10 <223>
 <220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Daba
 15 <220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> Daba
 <400> 21
 20

Cys Tyr Val Xaa Asn Cys Pro Xaa Ala
1 5

25
 <210> 22
 <211> 9
 <212> PRT
 30 <213> PEPTIDE
 <220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> AMIDATION
 35 <220>
 <221> DISULFID
 <222> (1)..(6)
 <223>
 <220>
 40 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> Hoph
 <220>
 <221> MISC_FEATURE
 45 <222> (4)..(4)
 <223> Daba
 <220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 50 <223> Cit
 <400> 22

Cys Tyr Xaa Xaa Asn Cys Pro Xaa Ala
1 5

<210> 23
 <211> 9
 <212> PRT
 <213> PEPTIDE
 5 <220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> AMIDATION
 <220>
 10 <221> DISULFID
 <222> (1)..(6)
 <223>
 <400> 23


Cys Tyr Phe Arg Asn Cys Pro Val Ala
 1 5

20 <210> 24
 <211> 9
 <212> PRT
 <213> PEPTIDE
 <220>
 25 <221> MOD_RES
 <222> (9)..(9)
 <223> AMIDATION
 <220>
 30 <221> THIOETH
 <222> (1)..(6)
 <223>
 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 35 <223> Mpa
 <220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> (O-methyl-Tyr)
 40 <400> 24

Xaa Xaa Ile Gln Asn Cys Pro Leu Gly
 1 5

Claims

- 50
1. Use of at least one substance with oxytocin activity for the preparation of a pharmaceutical composition against a pre-cancerous disease state in the cervix and cervicitis.
 2. Use according to Claim 1, **characterised in that** the at least one substance is selected from the group consisting of the following compounds:
- 55



5

wherein

X₁ is selected from the group consisting of Cys, Mpa and nothing,

10

X₂ is selected from the group consisting of Tyr, (O-methyl-Tyr), Phe, and nothing, X₃ is selected from the group consisting of Ile, Val, Hoph, Phe, Cha, and nothing, X₄ is selected from the group consisting of Gln, Ser, Thr, Cit, Arg, and Daba, X₅ is selected from the group consisting of Pro, and nothing,

X₆ is selected from the group consisting of Ile, Leu, nothing, Val, Hos, Daba, Thr, Arg, and Cit,

X₇ is selected from the group consisting of Gly, nothing, and Ala,

X₈ is selected from the group consisting of Gly, and nothing,

15

X₉ is selected from the group consisting of CH₂ and S; as well as salts thereof.

3. Use according to Claim 1-2, **characterised in that** the at least one substance is selected from the group consisting of the following compounds: SEQ ID NO :1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.

20

4. Use according to Claim 1-3, **characterised in that** the pharmaceutical composition comprises substances that increase the release of oxytocin and/or the number or affinity of oxytocin receptors, such as oestrogen, or drugs having an α₂-agonistic effect, such as clonidine.

25

5. Use according to Claim 1-4, **characterised in that** the at least one substance is to be administered in amount of 0.01-100 ng/kg body weight of the patient.

30


6. Use according to Claim 1-5, **characterised in that** the at least one substance is to be administered in amount of 0.1-10 ng/kg body weight of the patient.

7. At least one substance with oxytocin activity for use in the treatment of a pre-cancerous disease state in the cervix and cervicitis.

35

8. At least one substance with oxytocin activity for use according to claim 7, **characterised in that** the at least one substance is selected from the group consisting of the following compounds:

40



45

wherein

X₁ is selected from the group consisting of Cys, Mpa and nothing,

X₂ is selected from the group consisting of Tyr, (O-methyl-Tyr), Phe, and nothing, X₃ is selected from the group consisting of Ile, Val, Hoph, Phe, Cha, and nothing, X₄ is selected from the group consisting of Gln, Ser, Thr, Cit, Arg, and Daba,

50

X₅ is selected from the group consisting of Pro, and nothing,

X₆ is selected from the group consisting of Ile, Leu, nothing, Val, Hos, Daba, Thr, Arg, and Cit,

X₇ is selected from the group consisting of Gly, nothing, and Ala,

X₈ is selected from the group consisting of Gly, and nothing,

55

X₉ is selected from the group consisting of CH₂ and S; as well as salts thereof.


9. At least one substance with oxytocin activity for use according to any of claims 7-8, **characterised in that** the at least one substance is selected from the group consisting of the following compounds: SEQ ID NO :1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ

ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.

- 5 10. At least one substance with oxytocin activity for use according to any of claims 7-9, **characterised in** being present in a pharmaceutical composition which comprises substances that increase the release of oxytocin and/or the number or affinity of oxytocin receptors, such as oestrogen, or drugs having an α_2 -agonistic effect, such as clonidine.
- 10 11. At least one substance with oxytocin activity for use according to any of claims 7-10, **characterised in that** the at least one substance is to be administered in amount of 0.01-100 ng/kg body weight of the patient.
12. At least one substance with oxytocin activity for use according to any of claims 7-11, **characterised in that** the at least one substance is to be administered in amount of 0.1-10 ng/kg body weight of the patient.

15 **Patentansprüche**

1. Verwendung wenigstens einer Substanz mit Oxytocin-Aktivität für die Herstellung einer pharmazeutischen Zusammensetzung gegen einen präkanzerösen Erkrankungszustand in der Zervix und Zervizitis.
- 20 2. Verwendung nach Anspruch 1, **dadurch gekennzeichnet, dass** die wenigstens eine Substanz aus der Gruppe ausgewählt ist, die aus den folgenden Verbindungen besteht:




30 worin

- X₁ aus der Gruppe, bestehend aus Cys, Mpa und Nichts, ausgewählt ist,
 X₂ aus der Gruppe, bestehend aus Tyr, (O-Methyl-Tyr), Phe und Nichts, ausgewählt ist,
 X₃ aus der Gruppe, bestehend aus Ile, Val, Hoph, Phe, Cha und Nichts, ausgewählt ist,
 X₄ aus der Gruppe, bestehend aus Gln, Ser, Thr, Cit, Arg und Daba, ausgewählt ist,
 35 X₅ aus der Gruppe, bestehend aus Pro und Nichts, ausgewählt ist,
 X₆ aus der Gruppe, bestehend aus Ile, Leu, Nichts, Val, Hos, Daba, Thr, Arg und Cit, ausgewählt ist,
 X₇ aus der Gruppe, bestehend aus Gly, Nichts und Ala, ausgewählt ist,
 X₈ aus der Gruppe, bestehend aus Gly und Nichts, ausgewählt ist,
 X₉ aus der Gruppe, bestehend aus CH₂ und S, ausgewählt ist, sowie Salzen davon.

- 40 3. Verwendung nach Anspruch 1 bis 2, **dadurch gekennzeichnet, dass** die wenigstens eine Substanz aus der Gruppe ausgewählt ist, die aus den folgenden Verbindungen besteht: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 und SEQ ID NO: 24.
4. Verwendung nach Anspruch 1 bis 3, **dadurch gekennzeichnet, dass** die pharmazeutische Zusammensetzung Substanzen, die die Freisetzung von Oxytocin und/oder die Anzahl oder Affinität von Oxytocin-Rezeptoren erhöhen, zum Beispiel Östrogen, oder Wirkstoffe, die α_2 -agonistische Wirkung haben, zum Beispiel Clonidin, umfasst.
- 50 5. Verwendung nach Anspruch 1 bis 4, **dadurch gekennzeichnet, dass** die wenigstens eine Substanz in einer Menge von 0,01-100 ng/kg Körpergewicht des Patienten zu verabreichen ist.
6. Verwendung nach Anspruch 1 bis 5, **dadurch gekennzeichnet, dass** die wenigstens eine Substanz in einer Menge von 0,1-10 ng/kg Körpergewicht des Patienten zu verabreichen ist.
- 55 7. Wenigstens eine Substanz mit Oxytocin-Aktivität zur Verwendung bei der Behandlung eines präkanzerösen Erkrankungszustandes in der Cervix und von Cervizitis.

8. Wenigstens eine Substanz mit Oxytocin-Aktivität zur Verwendung nach Anspruch 7, **dadurch gekennzeichnet, dass** die wenigstens eine Substanz aus der Gruppe ausgewählt ist, die aus den folgenden Verbindungen besteht:



10 worin

- X₁ aus der Gruppe, bestehend aus Cys, Mpa und Nichts, ausgewählt ist,
 X₂ aus der Gruppe, bestehend aus Tyr, (O-Methyl-Tyr), Phe und Nichts, ausgewählt ist,
 X₃ aus der Gruppe, bestehend aus Ile, Val, Hoph, Phe, Cha und Nichts, ausgewählt ist,
 X₄ aus der Gruppe, bestehend aus Gln, Ser, Thr, Cit, Arg und Daba, ausgewählt ist,
 15 X₅ aus der Gruppe, bestehend aus Pro und Nichts, ausgewählt ist,
 X₆ aus der Gruppe, bestehend aus Ile, Leu, Nichts, Val, Hos, Daba, Thr, Arg und Cit, ausgewählt ist,
 X₇ aus der Gruppe, bestehend aus Gly, Nichts und Ala, ausgewählt ist,
 X₈ aus der Gruppe, bestehend aus Gly und Nichts, ausgewählt ist,
 X₉ aus der Gruppe, bestehend aus CH₂ und S, ausgewählt ist, sowie Salzen davon.

20

9. Wenigstens eine Substanz mit Oxytocin-Aktivität zur Verwendung nach einem der Ansprüche 7 bis 8, **dadurch gekennzeichnet, dass** die wenigstens eine Substanz aus der Gruppe ausgewählt ist, die aus den folgenden Verbindungen besteht: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 und SEQ ID NO: 24.

25

10. Wenigstens eine Substanz mit Oxytocin-Aktivität zur Verwendung nach einem der Ansprüche 7 bis 9, **dadurch gekennzeichnet, dass** sie in einer pharmazeutischen Zusammensetzung vorliegt, welche Substanzen, die die Freisetzung von Oxytocin und/oder die Anzahl oder Affinität von Oxytocin-Rezeptoren erhöht, zum Beispiel Östrogen, oder Wirkstoffe, die α₂-agonistische Wirkung haben, zum Beispiel Clonidin, umfasst.

30

11. Wenigstens eine Substanz mit Oxytocin-Aktivität zur Verwendung nach einem der Ansprüche 7 bis 10, **dadurch gekennzeichnet, dass** die wenigstens eine Substanz in einer Menge von 0,01 bis 100 ng/kg Körpergewicht des Patienten zu verabreichen ist.

35

12. Wenigstens eine Substanz mit Oxytocin-Aktivität zur Verwendung nach einem der Ansprüche 7 bis 11, **dadurch gekennzeichnet, dass** die wenigstens eine Substanz in einer Menge von 0,1 bis 10 ng/kg Körpergewicht des Patienten zu verabreichen ist.


40

Revendications

1. Utilisation d'au moins une substance à activité sur l'ocytocine pour la préparation d'une composition pharmaceutique contre un état pathologique précancéreux dans le col de l'utérus et la cervicite.
2. Utilisation suivant la revendication 1, **caractérisée en ce qu'**au moins une substance est choisie dans le groupe consistant en les composés suivants :

45

50




55

- dans lesquels
 X₁ est choisi dans le groupe consistant en Cys, Mpa et rien,
 X₂ est choisi dans le groupe consistant en Tyr, (O-méthyl-Tyr), Phe et rien,
 X₃ est choisi dans le groupe consistant en Ile, Val, Hoph, Phe, Cha et rien,

EP 1 370 277 B1

X_4 est choisi dans le groupe consistant en Gln, Ser, Thr, Cit, Arg et Daba,
 X_5 est choisi dans le groupe consistant en Pro et rien, X_6 est choisi dans le groupe consistant en Ile, Leu, rien, Val, Hos, Daba, Thr, Arg et Cit,
 X_7 est choisi dans le groupe consistant en Gly, rien et Ala,
 X_8 est choisi dans le groupe consistant en Gly et rien, X_9 est choisi dans le groupe consistant en CH_2 et S ;
 et leurs sels.

3. Utilisation suivant les revendications 1 et 2, **caractérisée en ce qu'**au moins une substance est choisie dans le groupe consistant en les composés suivants : SEQ ID N° 1, SEQ ID N° 3, SEQ ID N° 4, SEQ ID N° 5, SEQ ID N° 6, SEQ ID N° 7, SEQ ID N°8, SEQ ID N° 9, SEQ ID N° 10, SEQ ID N° 11, SEQ ID N°12, SEQ ID N° 13, SEQ ID N° 14, SEQ ID N° 15, SEQ ID N° 16, SEQ ID N° 17, SEQ ID N° 18, SEQ ID N° 19, SEQ ID N° 20, SEQ ID N° 21, SEQ ID N° 22, SEQ ID N° 23 et SEQ ID N° 24.
4. Utilisation suivant les revendications 1 à 3, **caractérisée en ce que** la composition pharmaceutique comprend des substances qui augmentent la libération d'ocytocine et/ou le nombre ou l'affinité des récepteurs d'ocytocine, telles qu'un estrogène, ou des médicaments ayant un effet α_2 -agoniste, tels que la clonidine.
5. Utilisation suivant les revendications 1 à 4, **caractérisée en ce qu'**au moins une substance doit être administrée en une quantité de 0,01 à 100 ng/kg de poids corporel du patient.
6. Utilisation suivant les revendications 1 à 5, **caractérisée en ce qu'**au moins une substance doit être administrée en une quantité de 0,1 à 10 ng/kg de poids corporel du patient.
7. Au moins une substance à activité sur l'ocytocine, destinée à être utilisée dans le traitement d'un état pathologique précancéreux dans le col de l'utérus et de la cervicite.
8. Au moins une substance à activité sur l'ocytocine destinée à être utilisée suivant la revendication 7, ladite au moins une substance étant **caractérisée en ce qu'**elle est choisie dans le groupe consistant en les composés suivants



dans lesquels
 X_1 est choisi dans le groupe consistant en Cys, Mpa et rien,
 X_2 est choisi dans le groupe consistant en Tyr, (O-méthyl-Tyr), Phe et rien,
 X_3 est choisi dans le groupe consistant en Ile, Val, Hoph, Phe, Cha et rien,
 X_4 est choisi dans le groupe consistant en Gln, Ser, Thr, Cit, Arg et Daba,
 X_5 est choisi dans le groupe consistant en Pro et rien, X_6 est choisi dans le groupe consistant en Ile, Leu, rien, Val, Hos, Daba, Thr, Arg et Cit,
 X_7 est choisi dans le groupe consistant en Gly, rien et Ala,
 X_8 est choisi dans le groupe consistant en Gly et rien, X_9 est choisi dans le groupe consistant en CH_2 et S ;
 et leurs sels.

9. Au moins une substance à activité sur l'ocytocine destinée à être utilisée suivant l'une quelconque des revendications 7 et 8, ladite au moins une substance étant **caractérisée en ce qu'**elle choisie dans le groupe consistant en les composés suivants : SEQ ID N° 1, SEQ ID N° 3, SEQ ID N° 4, SEQ ID N° 5, SEQ ID N° 6, SEQ ID N° 7, SEQ ID N°8, SEQ ID N° 9, SEQ ID N° 10, SEQ ID N° 11, SEQ ID N°12, SEQ ID N° 13, SEQ ID N° 14, SEQ ID N° 15, SEQ ID N° 16, SEQ ID N° 17, SEQ ID N° 18, SEQ ID N° 19, SEQ ID N° 20, SEQ ID N° 21, SEQ ID N° 22, SEQ ID N° 23 et SEQ ID N° 24.
10. Au moins une substance à activité sur l'ocytocine destinée à être utilisée suivant l'une quelconque des revendications 7 à 9, **caractérisée en ce qu'**elle est présente dans une composition pharmaceutique qui comprend des substances qui augmentent la libération d'oxytocine et/ou le nombre ou l'affinité des récepteurs d'oxytocine, tels qu'un estrogène ou des médicaments ayant un effet α^2 -agoniste, tels que la clonidine.
11. Au moins une substance à activité sur l'ocytocine destinée à être utilisée suivant l'une quelconque des revendications

EP 1 370 277 B1

7 à 10, ladite au moins une substance étant **caractérisée en ce qu'**elle doit être administrée en une quantité de 0,01 à 100 ng/kg de poids corporel du patient.

- 5 **12.** Au moins une substance à activité sur l'ocytocine destinée à être utilisée suivant l'une quelconque des revendications 7 à 11, ladite au moins une substance étant **caractérisée en ce qu'**elle doit être administrée en une quantité de 0,1 à 10 ng/kg de poids corporel du patient.

10

15

20

25

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 2938891 A [0017]
- US 3076797 A [0017]
- EP 0660210 A2 [0023]
- SE 01006840 [0044]

Non-patent literature cited in the description

- **Bussolati et al.** *Cancer Research*, June 2001, vol. 61, 4393-4397 [0009]
- **Cassoni et al.** *Journal of Pathology*, 2000, vol. 190, 470-477 [0009]
- **van Zandwijk et al.** *J Cell Biochem*, 1995, vol. 22, 24-32 [0009]
- **Oumi T ; Ukena K ; Matsushima O ; Ikeda T ; Fujita T ; Minakata H ; Nomoto K.** Annetocin: an oxytocin-related peptide isolated from the earthworm, *Eisenia foetida*. *Biochem Biophys Res Commun*, 14 January 1994, vol. 198 (1), 393-399 [0019]
- **Atke A ; Vilhardt H.** *Acta Endocrinologica (Copenh)*, 1987, vol. 115, 155-160 [0019]
- **Merrifield, P.B.** Solid Phase Synthesis. *Angew. Chemie*, 1985, 801 [0024]
- **Hirvonen, J. ; Kalia, YN ; Guy, RH.** Transdermal delivery of peptides by iontophoresis. *Nat Biotechnol*, December 1996, vol. 14 (13), 1710-1713 [0036]